netbook
desktop
mobile
tablet-landscape
tablet
phone-landscape
phone
Research to Prevent Blindness

Groundbreaking Gene Therapy for Retinal Disease

In March, a 13-year-old boy, Jack Hogan, was the first patient to receive an FDA-approved gene therapy for inherited blindness called Luxturna. The treatment, administered by RPB-supported researchers and physicians at Massachusetts Eye and Ear, is designed to improve visual function in children and adults with inherited retinal disease caused by mutations in the gene RPE65. The lead surgeon is an RPB Career Development Awardee, Jason Comander, MD, PhD, Associate Director of the Inherited Retinal Disorders Service at Mass. Eye and Ear. 

According to Mass. Eye and Ear, Luxturna involves injecting a modified virus into a patient’s eyes to correct a deficiency caused by mutations in the RPE65 gene. These mutations prevent the production or function of a protein needed for proper functioning of the retina, the light-sensitive tissue in the back of the eye that initiates vision. 

Dr. Jason Comander, lead surgeon, and patient Jack Hogan.

 

Photo credit: Massachusetts Eye and Ear

Since receiving his treatment, Hogan has experienced a significant impact on his quality of life. He’s enjoying better vision in low light, such as when playing basketball outside in the evening with friends or going to the movies, and is reading 40 percent smaller print.

"It is truly amazing to see large improvements in Jack’s vision, which would have been impossible without this treatment," said Dr. Comander.  "It is going to make a big difference in his life. These results are representative of just how big a moment this is for gene therapy; it is helping our patients and it is here to stay."

Related News: Feature Story, Gene Therapy, Retina Disorders , Top Story

Giving Tuesday logo

RPB Supporters Save Sight on Giving Tuesday

We welcome your generosity to help us meet our goal!

Read More

 
Dr. Palczewski and lab members

An RPB Awardee Tackles Inherited Retinal Diseases

Dr. Krzysztof Palczewski develops and applies cutting-edge gene editing techniques to challenging genetic conditions.

Read More

 
Dr. David Calkins

RPB and Association of University Professors of Ophthalmology Announce 2023 Recipient of RPB David F. Weeks Award for Outstanding Vision Research

David J. Calkins, PhD, is recognized for ground-breaking contributions to the field of vision research.

Read More

 
RPB logo

Research to Prevent Blindness and the American Academy of Ophthalmology Award New Research Grants to Improve Eye Care

Award recipients to use the American Academy of Ophthalmology IRIS® Registry (Intelligent Research in Sight) clinical database to improve care for all patients.

Read More

 
RPB logo

Grant from Research to Prevent Blindness and Castle Biosciences Supports Medical Student Research in Ocular Cancer

Research to Prevent Blindness and Castle Biosciences are partnering to provide new opportunities for medical students to pursue ocular cancer research.

Read More

 
RPB logo

New Glaucoma Research Grant Available

Research to Prevent Blindness and Aerie Pharmaceuticals are partnering to provide grant opportunities to support novel research in glaucoma.

Read More

 

Subscribe

Get our email updates filled with the latest news from our researchers about preventing vision loss, treating eye disease and even restoring sight. Unsubscribe at any time. Under our privacy policy, we'll never share your contact information with a third party.